Workflow
Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing
GlobeNewswire News Room·2025-08-04 11:33

Core Viewpoint - Quantum BioPharma Ltd. has filed a memorandum of law opposing a joint motion to dismiss by CIBC World Markets and RBC Dominion Securities, alleging market manipulation that harmed the company's stock price and seeking over $700 million in damages [1][2]. Legal Proceedings - The company filed an amended complaint on May 31, 2025, alleging that the defendants engaged in market manipulation schemes violating the Securities Exchange Act of 1934 [2]. - The lawsuit claims that from January 1, 2020, to August 15, 2024, the defendants used "spoofing" techniques to manipulate Quantum BioPharma's share price [2][4]. - The company has made all relevant legal documents available on its website for public access [3]. Financial Impact - Quantum BioPharma's stock was trading over $460 per share in January 2020, with a market capitalization nearing $1 billion [5]. - The company is seeking damages exceeding $700 million due to the alleged manipulation, which it claims has significantly harmed both the company and its investors [2][4]. Legal Representation - The law firms Christian Attar and Freedman Normand Friedland LLP are representing Quantum BioPharma on a contingency basis, meaning the company will not face immediate financial pressure for legal costs [4]. - These firms have conducted extensive investigations and believe there is sufficient evidence to support the claims of market manipulation [4]. Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [9]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [10]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc., with a royalty agreement that could yield significant future revenue [10].